Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Cencora (COR) has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with ...

Feb 5 (Reuters) - Drug distributor Cencora (COR.N), opens new tab raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines. The Conshohocken ...

Hello and welcome everyone to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky and I’ll be your Operator today. During the presentation, you can register a question by pressing ...

Baird raised the firm’s price target on Cencora (COR) to $307 from $305 and keeps an Outperform rating on the shares. The firm noted it was another beat and raise quarter. Published first on ...

Cencora, a global healthcare company, has expanded its Sure Supply Program to include 200 critical medications, including several oncology treatments, in response to ongoing drug shortages.

Walgreens is offloading more shares in drug distributor Cencora as the struggling pharmacy chain looks to generate cash. The latest sale netted about $300 million for Walgreens, and shrinks the ...

Over the past year, many Cencora, Inc. ( NYSE:COR ) insiders sold a significant stake in the company which may have... CONSHOHOCKEN, Pa., February 07, 2025--Cencora, Inc. (NYSE: COR) today ...

Feb 6 (Reuters) - U.S. drugstore chain Walgreens Boots Alliance (WBA.O), opens new tab said on Thursday it has sold more shares in drug distributor Cencora (COR.N), opens new tab for proceeds of ...

Cencora's Q1 sales rose 12.8% to $81.5B, surpassing the estimate, driven by GLP-1 drug sales and specialty product growth. Adjusted EPS grew 13.7% to $3.73, topping the consensus. FY25 EPS outlook ...

Mauch emphasized the strategic alignment of the RCA acquisition with Cencora’s pharmaceutical-centric strategy. CFO James Cleary noted, "Cencora delivered strong results in the first quarter ...